SEC Form 4
Replimune Group, Inc. (REPL) insider trading
In the 12 months to Nov 19, 2026, 4 REPL insiders reported open-market sales of $420.6K across 5 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $420.6K
- 5 filings · 4 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 3 of 5
- $274.2K of $420.6K sold (65%)
Who traded REPL, and when
- Sale
- Sale, pre-arranged (10b5-1)
REPL daily close from Nov 19, 2025 to Nov 18, 2026, between $1.70 and $23.28, last $19.81. 5 sale and 0 purchase filings by 4 insiders, marked at their filing dates. Christopher Sarchi, Chief Commercial Officer: sold $162.9K across 2 filings, first filed Apr 6, 2026, last Jun 3, 2026. Joseph P. Slattery, Director: sold $113.4K across 1 filing, first filed Nov 10, 2026, last Nov 10, 2026. Sushil Patel, Chief Executive Officer: sold $111.3K across 1 filing, first filed Dec 4, 2025, last Dec 4, 2025. Kapil Dhingra, Director: sold $33.0K across 1 filing, first filed Dec 11, 2025, last Dec 11, 2025.
Largest mark · tap a row for others
Joseph P. Slattery · Director
Sale $113,360
5,200 shares at $21.80 avg
Filed Nov 10, 2026 · traded Nov 9
Close on filing date $23.28
Christopher Sarchi · Chief Commercial Officer
Chief Commercial Officer
$162.9K soldJoseph P. Slattery · Director
Director
$113.4K soldSushil Patel · Chief Executive Officer
Chief Executive Officer
$111.3K soldKapil Dhingra · Director
Director
$33.0K soldOpen-market trades
5 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Christopher Sarchi | Chief Commercial Officer | $162.9K | — | 2 | 100% of sales | |
| Joseph P. Slattery | Director | $113.4K | — | 1 | — | |
| Sushil Patel | Chief Executive Officer | $111.3K | — | 1 | 100% of sales | |
| Kapil Dhingra | Director | $33.0K | — | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Joseph P. Slattery Director | Sale | 5,200 | $21.80 | $113.4K | 1,467 | |
traded | Christopher Sarchi Chief Commercial Officer | SalePre-arranged (10b5-1) | 12,000 | $9.24 | $110.9K | 180,962 | |
traded | Christopher Sarchi Chief Commercial Officer | SalePre-arranged (10b5-1) | 6,500 | $8.01 | $52.1K | 151,588 | |
traded | Kapil Dhingra Director | Sale | 3,169 | $10.40 | $33.0K | 0 | |
traded | Sushil Patel Chief Executive Officer | SalePre-arranged (10b5-1) | 10,000 | $11.13 | $111.3K | 333,576 |
GET /stocks/filings/vX/form-4?tickers=REPL&filing_date.gte=2025-11-19&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"REPL"
],
"issuer_cik": "0001737953",
"owner_cik": "0001246530",
"accession_number": "0001104659-26-125235",
"form_type": "4",
"filing_date": "2026-11-10",
"period_of_report": "2026-11-09",
"issuer_name": "Replimune Group, Inc.",
"issuer_trading_symbol": "REPL",
"owner_name": "SLATTERY JOSEPH P",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-11-09",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 5200,
"transaction_price_per_share": 21.8,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 1467,
"transaction_value": 113360,
"not_subject_to_section_16": false,
"direct_or_indirect": "D"
},
{
"tickers": [
"REPL"
],
"issuer_cik": "0001737953",
"owner_cik": "0001986597",
"accession_number": "0001104659-26-070256",
"form_type": "4",
"filing_date": "2026-06-03",
"period_of_report": "2026-06-01",
"issuer_name": "Replimune Group, Inc.",
"issuer_trading_symbol": "REPL",
"owner_name": "Sarchi Christopher",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Commercial Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-06-01",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 12000,
"transaction_price_per_share": 9.24,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 180962,
"transaction_value": 110880,
"not_subject_to_section_16": true,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The sales reported on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on December 15, 2025, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended."
},
{
"id": "F2",
"description": "The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $9.15 to $9.62 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 33 records
- Option exercises2 records
- Tax withholding (sold to cover)18 records
- Grants and awards11 records
- Gifts2 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Replimune Group, Inc.'s CEO sold stock?
Yes. Sushil Patel (CEO) sold 10,000 shares ($111.3K) in Dec 2025, all under a pre-arranged 10b5-1 plan.
How current is REPL’s insider data?
These are REPL Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track REPL insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for REPL every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.